Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elzovantinib (TPX-0022) in MET-altered solid tumors
NCT03993873Phase 1Active, not recruiting
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Sep 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of elzovantinib in non-small cell lung cancer (NSCLC), gastric cancer (GC) and solid tumor, sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days and Recommended Phase 2 Dose at 48 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
elzovantinib
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT03993873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993873.